SCC、CYFRA21-1联检对食管癌的诊断价值以及对放疗疗效评估

Conbined Determination of Serum SCC and CYFRA21-1 Levels on the Diagnostic Value of Esophageal Cancer and Assessment of Radiotherapeutic Efficacy

目的:通过联检血清鳞状上皮细胞癌相关抗原(SCC)及细胞角蛋白19片段(CYFRA21-1)的含量,观察其对食管癌的临床诊断价值以及疗效观察价值。方法:247例食管癌患者、45例正常人血清样品用全自动快速粒子酶免疫分析系统(IMX)测定SCC及CYFRA21-1的含量。结果:与正常人血清相比,食管癌患者血清SCC及CYFRA21-1含量明显升高,两项标志物阳性检出率分别为22.7%和39.3%,两者联检阳性率为48.9%。随着食管癌分期的增加,SCC以及CYFRA21-1阳性率增高。食管癌患者血清SCC、CYFRA21-1含量在治疗后与治疗前相比有显著性差异(P<0.05)。结论:SCC及CYFRA21-1测定对食管癌的良恶性辅助诊断具有一定的应用价值,联检不仅可提高食管癌的阳性诊断率,对食管癌的放射治疗疗效监测也具有重要价值。

Objective To investigate the usefulness of dynamic combined measurement of serum SCC and CYFRA21-1 contents in diagnosis and treatment efficacy assessment in patients with esophageal cancer.Methods Serum SCC and CYFRA21-1 contents were measured with IMX in 247 patients with esophageal cancer both before and after radiotherapy,45 normal heslthy controls.Results Serum SCC and CYFRA21-1 contents in patients with esophageal cancer were significantly higher than those in patients with controls,the diagnositic sensitivity of SCC and CYFRA21-1 for esophageal cancer was 22.7% and 39.3% respectively,with 48.9% for combined determination of the two markers.the later the clinical stage,the higher the sensitivity of serum SCC and CYFRA21-1 was.In the esophageal cancer patients,the concentrations of the markers dropped apparently after radiotherapy（P0.05）.Conclusion Combined determination of serum SCC and CYFRA21-1 contents would increase the diagnostic sensitivity for esophageal cancer and also valuable for assessment of the therapeutic efficacy of radiotherapy.